logo of US biotech company Novavax. Novavax’s vaccine targets the JN.1 COVID-19 variant, which was the dominant strain circulating in the U.S. earlier this year but now makes up less than 1% of ...

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced that doses of the Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 ...

Therefore, knowing a company's potential revenue growth is crucial. For Novavax, the consensus sales estimate for the current quarter of $54.41 million indicates a year-over-year change of -70.9%.

Novavax, Inc. (Nasdaq: NVAX), a global company advancing protein-based vaccines with its Matrix-M™ adjuvant, today announced ...

The Food and Drug Administration approved an updated coronavirus vaccine manufactured by Novavax Friday, days after new mRNA coronavirus vaccines manufactured by Pfizer-BioNTech and Moderna ...

Novavax Inc. closed $10.66 short of its 52-week high ($23.86), which the company reached on June 6th. Supported by ...

J.P. Morgan analyst Eric Joseph maintained a Sell rating on Novavax (NVAX – Research Report) yesterday and set a price target of $9.00. The company’s shares closed yesterday at $11.85.

Novavax said the licensing agreement allows the company to remove its "going concern" warning, which it first issued last ...

Novavax's protein-based Coronavirus vaccine has been recommended by the US CDC for adolescents aged 12-17 years old after receiving emergency use authorization for adults in June. Biotech company ...

Shares of Novavax Inc. NVAX slid 2.86% to $12.56 Wednesday, on what proved to be an all-around dismal trading session for the ...